Compare SACH & ATNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SACH | ATNM |
|---|---|---|
| Founded | 2010 | 2000 |
| Country | United States | United States |
| Employees | 29 | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 48.6M | 36.8M |
| IPO Year | N/A | 2013 |
| Metric | SACH | ATNM |
|---|---|---|
| Price | $1.08 | $1.19 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 3 | 1 |
| Target Price | $2.00 | ★ $4.00 |
| AVG Volume (30 Days) | ★ 128.9K | 115.6K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 18.52% | N/A |
| EPS Growth | N/A | ★ 30.60 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $81,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $1.17 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.80 | $1.02 |
| 52 Week High | $1.35 | $1.95 |
| Indicator | SACH | ATNM |
|---|---|---|
| Relative Strength Index (RSI) | 69.14 | 52.28 |
| Support Level | $1.04 | $1.02 |
| Resistance Level | $1.13 | $1.71 |
| Average True Range (ATR) | 0.03 | 0.07 |
| MACD | 0.01 | 0.02 |
| Stochastic Oscillator | 72.03 | 77.78 |
Sachem Capital Corp is a real estate investment trust. The company specializes in originating, underwriting, funding, servicing, and managing a portfolio of short-term loans secured by first mortgage liens on real property located in Connecticut. Its primary objective is to grow the loan portfolio while protecting and preserving capital in a manner that provides for attractive risk-adjusted returns to shareholders over the long term through dividends. The company earns majority of its revenue through Interest income from loans.
Actinium Pharmaceuticals Inc is a biopharmaceutical company engaged in the development of radiotherapies for patients with cancers lacking effective treatment options. The company's proprietary technology platform utilizes monoclonal antibodies to deliver radioisotopes directly to cells of interest to kill those cells safely and effectively. Its product candidates are Iomab-B, an antibody-drug construct containing iodine 131 (I-131), used for hematopoietic stem cells transplantation in various indications, and Actimab-A, an antibody-drug construct containing actinium 225 (Ac-225), currently in human clinical trials for acute myeloid leukemia.